Anti-hypertensive drugs have different effects on ventricular hypertrophy regression

Clinics (Sao Paulo). 2010 Jul;65(7):723-8. doi: 10.1590/S1807-59322010000700012.

Abstract

Objectives: There is a direct relationship between the regression of left ventricular hypertrophy (LVH) and a decreased risk of mortality. This investigation aimed to describe the effects of anti-hypertensive drugs on cardiac hypertrophy through a meta-analysis of the literature.

Methods: The Medline (via PubMed), Lilacs and Scielo databases were searched using the subject keywords cardiac hypertrophy, antihypertensive and mortality. We aimed to analyze the effect of anti-hypertensive drugs on ventricle hypertrophy.

Results: The main drugs we described were enalapril, verapamil, nifedipine, indapamina, losartan, angiotensin-converting enzyme inhibitors and atenolol. These drugs are usually used in follow up programs, however, the studies we investigated used different protocols. Enalapril (angiotensin-converting enzyme inhibitor) and verapamil (Ca(++) channel blocker) caused hypertrophy to regress in LVH rats. The effects of enalapril and nifedipine (Ca(++) channel blocker) were similar. Indapamina (diuretic) had a stronger effect than enalapril, and losartan (angiotensin II receptor type 1 (AT1) receptor antagonist) produced better results than atenolol (selective beta1 receptor antagonist) with respect to LVH regression.

Conclusion: The anti-hypertensive drugs induced various degrees of hypertrophic regression.

Keywords: Cardiology; Cardiomyopathy; Hypertrophic; Hypertrophy; Left ventricle hypertension.

Publication types

  • Meta-Analysis
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antihypertensive Agents / therapeutic use*
  • Humans
  • Hypertension / prevention & control
  • Hypertrophy, Left Ventricular / drug therapy*
  • Hypertrophy, Left Ventricular / mortality
  • Rats
  • Remission Induction / methods
  • Risk Factors
  • Treatment Outcome

Substances

  • Antihypertensive Agents